Limits...
Expression of the Transmembrane Glycoprotein CD44s Is Potentially an Independent Predictor of Recurrence in Hepatocellular Carcinoma.

Ryu HS, Park SH, Lee KB, Shin E, Jang JJ - Gut Liver (2011)

Bottom Line: The effect of CD44s expression on patient survival was analyzed.High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC.CD44s-targeted therapy may be efficacious for HCC treatment in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Cluster differentiation 44 standard isoform (CD44s) is a transmembrane glycoprotein. CD44s is a known prognostic factor in various cancers, due to its involvement in tumor cell growth, invasion and metastasis. Its prognostic role, however, is debated because it can be a positive or negative prognostic factor depending on tumor type and is still an ambiguous prognostic indicator in other cancers, especially hepatocellular carcinoma (HCC). We investigated the relationship between CD44s expression and survival in HCC patients.

Methods: A total of 260 HCC samples were collected to generate a tissue microarray. Staining of the arrays with a primary mouse CD44s monoclonal antibody was followed by evaluation of the relationship between CD44s expression and tumor differentiation. The effect of CD44s expression on patient survival was analyzed.

Results: CD44s protein expression correlated with histological grade (most and worst Edmondson grade) of the HCC (p=0.029 and p=0.039, respectively) and adversely affected the disease free survival period based on univariate and multivariate analyses (p=0.038 and p=0.077, respectively).

Conclusions: High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44s-targeted therapy may be efficacious for HCC treatment in the future.

No MeSH data available.


Related in: MedlinePlus

Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A), but there is no significant correlation between CD44s protein expression and overall survival (B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3140667&req=5

Figure 2: Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A), but there is no significant correlation between CD44s protein expression and overall survival (B).

Mentions: As Edmondson grade system was known for time honored prognostic factor and there was the relationship between CD44s and these classical grades system, we tried to evaluate correlation of CD44s expression with overall and disease-free survival length. According to the result of relationship between Edmondson grade and survival lengths, the patients with low Edmondson grade showed significant longer surviving perio d than those of higher grade (Tables 2 and 3). CD44s also showed shortened disease-free survival period in CD44s expressed patients group than negative expression group (p=0.038, Table 2, Fig. 2A). However no correlation between overall survival length and CD44s expression was identified (Table 3, Fig. 2B). There are 26 patients (10%) who died with no evidence of tumor recurrence and we evaluated survival analysis after exclusion of these patients, which showed similar results in disease-free survival in univariate analysis (p=0.026). In multivariate analysis, most Edmondson grade (p=0.001) and portal vein invasion (p=0.001) were independent predictors of recurrence. CD44s was seen as marginally significant risk factor of recurrence of disease (p=0.077) (Table 4). Tumor size was also revealed as one of significant independent variables for both overall and disease-free survival (p=0.004 and 0.015). Multivariate analysis of overall survival indicated no correlation between CD44s expression of the tumor (p=0.838) (Table 5).


Expression of the Transmembrane Glycoprotein CD44s Is Potentially an Independent Predictor of Recurrence in Hepatocellular Carcinoma.

Ryu HS, Park SH, Lee KB, Shin E, Jang JJ - Gut Liver (2011)

Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A), but there is no significant correlation between CD44s protein expression and overall survival (B).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3140667&req=5

Figure 2: Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A), but there is no significant correlation between CD44s protein expression and overall survival (B).
Mentions: As Edmondson grade system was known for time honored prognostic factor and there was the relationship between CD44s and these classical grades system, we tried to evaluate correlation of CD44s expression with overall and disease-free survival length. According to the result of relationship between Edmondson grade and survival lengths, the patients with low Edmondson grade showed significant longer surviving perio d than those of higher grade (Tables 2 and 3). CD44s also showed shortened disease-free survival period in CD44s expressed patients group than negative expression group (p=0.038, Table 2, Fig. 2A). However no correlation between overall survival length and CD44s expression was identified (Table 3, Fig. 2B). There are 26 patients (10%) who died with no evidence of tumor recurrence and we evaluated survival analysis after exclusion of these patients, which showed similar results in disease-free survival in univariate analysis (p=0.026). In multivariate analysis, most Edmondson grade (p=0.001) and portal vein invasion (p=0.001) were independent predictors of recurrence. CD44s was seen as marginally significant risk factor of recurrence of disease (p=0.077) (Table 4). Tumor size was also revealed as one of significant independent variables for both overall and disease-free survival (p=0.004 and 0.015). Multivariate analysis of overall survival indicated no correlation between CD44s expression of the tumor (p=0.838) (Table 5).

Bottom Line: The effect of CD44s expression on patient survival was analyzed.High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC.CD44s-targeted therapy may be efficacious for HCC treatment in the future.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: Cluster differentiation 44 standard isoform (CD44s) is a transmembrane glycoprotein. CD44s is a known prognostic factor in various cancers, due to its involvement in tumor cell growth, invasion and metastasis. Its prognostic role, however, is debated because it can be a positive or negative prognostic factor depending on tumor type and is still an ambiguous prognostic indicator in other cancers, especially hepatocellular carcinoma (HCC). We investigated the relationship between CD44s expression and survival in HCC patients.

Methods: A total of 260 HCC samples were collected to generate a tissue microarray. Staining of the arrays with a primary mouse CD44s monoclonal antibody was followed by evaluation of the relationship between CD44s expression and tumor differentiation. The effect of CD44s expression on patient survival was analyzed.

Results: CD44s protein expression correlated with histological grade (most and worst Edmondson grade) of the HCC (p=0.029 and p=0.039, respectively) and adversely affected the disease free survival period based on univariate and multivariate analyses (p=0.038 and p=0.077, respectively).

Conclusions: High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44s-targeted therapy may be efficacious for HCC treatment in the future.

No MeSH data available.


Related in: MedlinePlus